APA (7th ed.) Citation

DL, A., T, S., A, B., JS, W., L, K., S, K., . . . A, T. (2022). Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple sclerosis (Houndmills, Basingstoke, England), 28(12), 1927. https://doi.org/10.1177/13524585221097561

Chicago Style (17th ed.) Citation

DL, Arnold, et al. "Ocrelizumab Reduces Thalamic Volume Loss in Patients with RMS and PPMS." Multiple Sclerosis (Houndmills, Basingstoke, England) 28, no. 12 (2022): 1927. https://doi.org/10.1177/13524585221097561.

MLA (9th ed.) Citation

DL, Arnold, et al. "Ocrelizumab Reduces Thalamic Volume Loss in Patients with RMS and PPMS." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 28, no. 12, 2022, p. 1927, https://doi.org/10.1177/13524585221097561.